News


avanir22

PRISM Results Provide Insight into the Prevalence of PBA in Neurologic Patients

avanir22Avanir Pharmaceuticals announces that the results of the PBA Registry Series (PRISM) patient registry, encompassing data from 5,290 patients and the prevalence of pseudobulbar effect (PBA) in patients with a range of neurological conditions, have been published in PLOS ONE.

Patients enrolled by investigators exhibited six common neurologic conditions often linked to PBA. Avanir notes that PBA is characterized by emotional outbursts that are often contrary or exaggerated to the patient’s inner mood state, causing uncontrollable laughing or crying.

Researchers note that more than one third of the patients had a CNS-LS score ≥ 13, suggesting the presence of PBA symptoms. The results also indicate that the impact of the patients’ neurological condition on quality of life (QOL) was significantly higher in these patients.

Randall Kaye, MD, chief medical officer, Avanir Pharmaceuticals, explains that the results reinforce the common prevalence of PBA among patients with diverse neurologic conditions.

“Higher CNS-LS scores were associated with significantly worse quality of life scores and greater use of antipsychotic/antidepressant medications. Publication of this important information will help healthcare practitioners better appreciate the frequency and multi-faceted impact of PBA symptoms in their neurologic patients,” Kaye says.

Avanir notes that PRISM was designed to provide PBA symptom prevalence data in a large, representative US sample of patients in a clinical setting with neurological conditions known to be linked to PBA. Patients enrolled in the registry included 125 patients with amyotrophic lateral sclerosis (ALS), 1,799 patients with Alzheimer’s disease, 1,215 multiple sclerosis (MS) patients, 804 Parkinson’s disease patients, 757 stroke patients, and 590 patients with traumatic brain injuries (TBIs).

To read the registry’s findings, click here

To learn more about PBA click here

Source: Avanir Pharmaceuticals Inc